Clene Reports New Data from the VISIONARY-MS Phase 2 Study in Multiple Sclerosis Demonstrating CNM-Au8® Treatment Improved Brain Neuronal Structural Integrity MRI results reinforce the clinical neurological improvements previously reportedMRI results showed improved brain neuronal structural integrity, independent of an immunomodulatory effectMRI results...

Clene Reports Second Quarter 2022 Financial Results and Recent Operating Highlights Topline results from the Phase 2 VISIONARY-MS clinical trial with CNM-Au8® met the primary and secondary endpoints of Low Contrast Letter Acuity (LCLA) and modified Multiple Sclerosis Functional...

Clene Receives Positive EMA Opinion on Orphan Drug Designation for CNM-Au8® for the Treatment of ALS SALT LAKE CITY, July 19, 2022 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage...

Updated Interim Data from Clene Nanomedicine’s RESCUE-ALS Open-Label Extension Study to be Presented in Emerging Science Program at 2022 AAN Annual Meeting SALT LAKE CITY, April 01, 2022 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ: CLNN) along with its subsidiaries “Clene” and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage...